APH

ALDA Pharmaceuticals Corp. (TSX VENTURE: APH)(OTCQB: APCSF) (the "Company") announces that new tests have shown that T36® Antiseptic Hand Sanitizer is completely effective against two types of new "superbugs" within 15 seconds. The testing was conducted at BioScience Laboratories in Bozeman, MT against antibiotic-resistant strains of E. coli and Klebsiella. These strains have taken genes from other bacteria that have developed the ability to digest nearly all antibiotics, including penicillin-like antibiotics that possess broad spectrum antibacterial properties and are typically used as a last resort. Such genetic "swapping" is common among bacteria and is a major cause of antibiotic resistance.

Dr. Terrance Owen, President & CEO comments, "T36® Antiseptic Hand Sanitizer works in a completely different way than antibiotics. It kills infectious organisms by disrupting their cell walls so the presence of antibiotic-digesting enzymes does not stop it from working. Since these infections are so dangerous, it is important to prevent them from happening in the first place. Proper hygiene, including the use the of hand sanitizers and disinfectants such as T36® Antiseptic Hand Sanitizer and T36® Disinfectant, is a very important step in preventing the spread of potentially incurable diseases."

About ALDA Pharmaceuticals Corp.

ALDA is focused on the development of infection-control therapeutics derived from its patented T36® technology. The Company trades on the TSX Venture Exchange under the symbol APH and on the OTCQB under the symbol APCSF. The Company was the Official Supplier to the Vancouver 2010 Olympic Winter Games and the Vancouver 2010 Paralympic Winter Games and is the Official Supplier to the Canadian Olympic Committee, the 2010 Canadian Olympic Team and the 2012 Canadian Olympic Team for antiseptic hand sanitizer, disinfectant and disinfectant cleaning products. The Company was also selected as one of the TSX Venture 50 companies in the Technology and Life Sciences sector for 2010.

Terrance G. Owen, Ph.D., MBA, President & CEO

ALDA Pharmaceuticals Corp.

www.aldacorp.com

The Units, common shares, warrants and the common shares issuable upon exercise of the warrants have not been registered under the United States Securities Act of 1933 (the "Act") and may not be offered or sold absent registration under the Act or an applicable exemption from the registration requirements thereof. This news release does not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction or an exemption therefrom.

Cautionary Note Regarding Forward-looking Statements: Information in this press release that involves ALDA's expectations, plans, intentions or strategies regarding the future are forward-looking statements that are not facts and involve a number of risks and uncertainties. ALDA generally uses words such as "outlook", "will", "could", "would", "might", "remains", "to be", "plans", "believes", "may", "expects", "intends", "anticipates", "estimate", "future", "plan", "positioned", "potential", "project", "remain", "scheduled", "set to", "subject to", "upcoming", and similar expressions to help identify forward-looking statements. The forward-looking statements in this release are based upon information available to ALDA as of the date of this release, and ALDA assumes no obligation to update any such forward-looking statements. Forward-looking statements believed to be true when made may ultimately prove to be incorrect. These statements are not guarantees of the future performance of ALDA and are subject to risks, uncertainties and other factors, some of which are beyond its control and may cause actual results to differ materially from current expectations.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contacts: ALDA Pharmaceuticals Corp. Scott Young Investor Relations 604-377-5781 or 604-521-8300 Ext 203 604-521-8322 (FAX) scott_young@aldacorp.com www.aldacorp.com